Research analysts covering Scinai Immunotherapeutics.
Recent press releases and 8-K filings for SCNI.
Scinai Immunotherapeutics Reports Nine-Month 2025 Results, Highlights CDMO Growth and NanoAbs Pipeline Progress
SCNI
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- Revenues for the nine months ended September 30, 2025, increased to $1,049 thousand from $452 thousand in the prior year, reflecting continued expansion of its CDMO business.
- The company reported a net loss of $6,244 thousand for the nine months ended September 30, 2025, compared to a net profit of $7,026 thousand in the same period of 2024, primarily due to financial income from a loan conversion recognized in 2024.
- Scinai Bioservices received a non-dilutive grant of approximately $246,000 from the Israel Innovation Authority to fund an advanced sterile fill-and-finish system, with commercial operation planned for Q2 2026.
- The NanoAbs pipeline is advancing, with decisions on two separate EU STEP grant applications of up to €15 million each expected in Q1 2026.
- The PC111 program's €12 million FENG grant application was not approved, leading Scinai to evaluate strategic alternatives, including a new grant application or potentially terminating its option to acquire Pincell.
Dec 2, 2025, 4:00 PM
Scinai Immunotherapeutics Reports Nine-Month 2025 Results and Business Updates
SCNI
Earnings
New Projects/Investments
- Scinai Immunotherapeutics reported revenues of $1,049 thousand for the nine months ended September 30, 2025, an increase from $452 thousand in the same period of 2024, resulting in a net loss of $6,244 thousand compared to a net profit of $7,026 thousand in the prior year.
- The company's CDMO business, Scinai Bioservices, continues to expand, with its U.S. subsidiary contributing $502 thousand in revenues during the first nine months of 2025, and received a grant for a new sterile fill-and-finish system expected to be commercially operational in Q2 2026.
- In its R&D business, Scinai is advancing its NanoAb pipeline with decisions on two €15 million grant applications expected in Q1 2026, but a €12 million grant application for the PC111 program was not approved, leading to an evaluation of strategic alternatives for that program.
Dec 2, 2025, 1:50 PM
Scinai Immunotherapeutics Enters $15 Million Equity Purchase Agreement
SCNI
- Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. on September 10, 2025, granting the company the right, but not the obligation, to sell up to $15 million of its American Depositary Shares (ADSs) over a 36-month period.
- The purchase price for the ADSs will be 97% of the lowest of the three daily Volume Weighted Average Prices (VWAPs) during a three-consecutive trading day period, with the company able to specify a minimum acceptable price per ADS.
- A commitment fee of $108,000 is payable to the investor, with 50% paid by the issuance of 35,461 ADSs and the remaining 50% in cash.
- The investor's beneficial ownership is limited to 9.99% of the company's then-outstanding voting power or number of Ordinary Shares.
- This new agreement will automatically terminate a prior Standby Equity Purchase Agreement dated March 3, 2025, between the Company and Yorkville, upon the effectiveness of a new registration statement.
Sep 11, 2025, 11:49 AM
Scinai Immunotherapeutics Ltd. Reports Six-Month 2025 Financial Results
SCNI
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Scinai Immunotherapeutics Ltd. reported revenues of $773 thousand for the six months ended June 30, 2025, a significant increase from $284 thousand in the same period of 2024, reflecting continued growth in its CDMO business.
- The company's net loss for the six months ended June 30, 2025, was $4,134 thousand, a decrease from $4,481 thousand in the prior year, primarily due to higher revenues and lower R&D expenses.
- Research and development expenses for the six months ended June 30, 2025, amounted to $1,237 thousand, down from $2,788 thousand for the same period in 2024.
- As of June 30, 2025, cash and cash equivalents totaled $989 thousand. Subsequently, in July and August 2025, the company raised an additional $4.2 million through its Standby Equity Purchase Agreement.
- Scinai is advancing its anti-IL-17 NanoAb program and plans to apply for up to €15 million in grant financing under the EU STEP program, with a decision expected in Q1 2026.
Sep 2, 2025, 8:16 PM
Quarterly earnings call transcripts for Scinai Immunotherapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more